The HeLa cell line was established in 1951 from cervical cancer cells taken from a patient, Henrietta Lacks. This was the first successful attempt to immortalize human-derived cells in vitro 1 . The robust growth and unrestricted distribution of HeLa cells resulted in its broad adoption-both intentionally and through widespread crosscontamination 2 -and for the past 60 years it has served a role analogous to that of a model organism 3 . The cumulative impact of the HeLa cell line on research is demonstrated by its occurrence in more than 74,000 PubMed abstracts (approximately 0.3%). The genomic architecture of HeLa remains largely unexplored beyond its karyotype 4 , partly because like many cancers, its extensive aneuploidy renders such analyses challenging. We carried out haplotype-resolved wholegenome sequencing 5 of the HeLa CCL-2 strain, examined point-and indel-mutation variations, mapped copy-number variations and loss of heterozygosity regions, and phased variants across full chromosome arms. We also investigated variation and copy-number profiles for HeLa S3 and eight additional strains. We find that HeLa is relatively stable in terms of point variation, with few new mutations accumulating after early passaging. Haplotype resolution facilitated reconstruction of an amplified, highly rearranged region of chromosome 8q24.21 at which integration of the human papilloma virus type 18 (HPV-18) genome occurred and that is likely to be the event that initiated tumorigenesis. We combined these maps with RNA-seq 6 and ENCODE Project 7 data sets to phase the HeLa epigenome. This revealed strong, haplotype-specific activation of the proto-oncogene MYC by the integrated HPV-18 genome approximately 500 kilobases upstream, and enabled global analyses of the relationship between gene dosage and expression. These data provide an extensively phased, high-quality reference genome for past and future experiments relying on HeLa, and demonstrate the value of haplotype resolution for characterizing cancer genomes and epigenomes.
We generated a haplotype-resolved genome sequence of HeLa CCL-2 using a multifaceted approach that included shotgun, mate-pair and long-read sequencing, as well as sequencing of pools of fosmid clones 5 ( Supplementary Table 1 ). To catalogue variants, we carried out conventional shotgun sequencing to 883 non-duplicate coverage and reanalysed 11 control germline genomes in parallel 8 (Supplementary  Tables 2 and 3 ). Although normal tissue corresponding to HeLa is unavailable, the total number of single-nucleotide variants (SNVs) identified in HeLa CCL-2 (n 5 4.1 3 10 6 ) and the proportion overlapping with the 1000 Genomes Project 9 (90.2%) were similar to controls (mean n 5 4.2 3 10 6 and 87.7%, respectively), suggesting that HeLa has not accumulated appreciably large numbers of somatic SNVs relative to inherited variants. Indel variation was unremarkable after accounting for differences in coverage ( Supplementary Fig. 1 ). Short tandem repeat profiles of HeLa also resembled controls, consistent with mismatch repair proficiency ( Supplementary Fig. 2 ).
After removing protein-altering variants that overlapped with the 1000 Genomes Project or the Exome Sequencing Project 10 , similar numbers of private protein-altering (PPA) SNVs were found in HeLa (n 5 269) and controls (mean n 5 391). Gene ontology analysis found that all terms enriched for PPA variants in HeLa (P # 0.01) were also enriched in at least one control (except for 'startle response' in HeLa), suggesting that known cancer-related pathways are not perturbed extensively by point or indel mutations ( Supplementary Fig. 3 ). Although a previous study of the HeLa transcriptome 11 reported an enrichment of putative mutations in cell-cycle-and E2F-related genes, subsequently generated population-scale data sets contain all variants that we observed in these genes, suggesting that they are inherited and benign rather than somatic and pathogenic.
The overlap between PPA variants and the Catalogue of Somatic Mutations in Cancer (COSMIC) 12 was similar for HeLa (n 5 1) and control genomes (mean n 5 2.6). The gene-level overlap with the Sanger Cancer Gene Census (SCGC) 12 was also similar for HeLa (n 5 4) and control genomes (mean n 5 8.7). Canonical tumour suppressors and oncogenes were notably absent among the five SCGC genes with PPA variants in HeLa (BCL11B (B-cell CLL/lymphoma 11B (zinc finger protein)), EP300 (E1A binding protein p300), FGFR3 (fibroblast growth factor receptor 3), NOTCH1 and PRDM16 (PR domain containing 16), Supplementary Tables 3-6 ). However, three are associated with HPV-mediated oncogenesis (FGFR3, EP300, NOTCH1) and may be ancillary to the dominant role of HPV oncoproteins in HeLa and other HPV 1 cervical carcinomas 13 . Mutations in FGFR3 have been noted previously in cervical carcinomas, although infrequently and at different residues than observed here 14 . Both EP300 and NOTCH1 are recurrently mutated in diverse cancers and are involved in Notch signalling, a pathway that is dysregulated in HeLa 15 . EP300, which encodes the transcriptional co-activator p300, interacts directly with viral oncoproteins such as HPV-16 E6 and HPV-16 E7 (ref. 16) . Although the in-frame deletion of a highly conserved amino acid in EP300 seems to be somatic (heterozygous within a loss-of-heterozygosity (LOH) region), it is still possible that the others are rare, inherited variants or passenger mutations. Further studies are required to resolve their functional relevance and to assess whether these genes are recurrently altered in HPV 1 cervical carcinomas.
Aneuploidy and LOH, which are hallmarks of cancer genomes, were mapped in HeLa by constructing a digital copy-number profile at kilobase resolution ( Fig. 1, Supplementary Fig. 4 and Supplementary  Table 7 ). Read coverage profiles were segmented by a Hidden Markov Model (HMM) and recalibrated to account for widespread aneuploidy ( Supplementary Figs 5 and 6 ). Sixty-one per cent of the genome has a baseline copy number of three, and only a small minority (3%) has a copy number of greater than four or less than two (Supplementary Table 8 ). LOH encompassed 15.7% of the genome, including several entire chromosome arms (5p, 6q, Xp, Xq) or large distal portions (2q, 3q, 6p, 11q, 13q, 19p, 22q) ( Supplementary Fig. 7 and Supplementary Table 9 ), consistent with previous descriptions of LOH in cervical carcinomas 17 . The overall profile is consistent with published karyotypes of various HeLa strains 4 , suggesting that the hypertriploid state arose either during tumorigenesis or early in the establishment of the HeLa cell line.
Structural variants were identified by clustering discordantly mapped reads from 40-kb and 3-kb mate-pair libraries (Supplementary Fig. 8 ). Twenty interchromosomal links were identified, including links for marker chromosomes M11 (9q33-11p14) and M14 (13q21-19p13). In addition, 209 HeLa-specific deletions and 8 inversions were found ( Supplementary Figs 9 and 11 , and Supplementary Table 10 ). Only two genes that are impacted by HeLa-specific structural rearrangements ( Supplementary Table 11 ) intersected with SCGC (STK11 (ref. 18), FHIT), both of which are recurrently deleted in cervical carcinomas 18, 19 .
Conventional whole-genome sequencing fails to resolve haplotype phase, an essential aspect of the description and interpretation of nonhaploid genomes, including cancer genomes 20 . Recently, several groups have demonstrated genome-wide measurement of local 5 or sparse 21 haplotypes, but these approaches have yet to be applied to aneuploid cancer genomes. To resolve haplotype phase across the HeLa genome, we sequenced pools of fosmid clones 5 . Specifically, we constructed three complex fosmid-clone libraries, and then carried out limiting dilution and shotgun sequencing of 288 fosmid clone pools. In summary, these were estimated to include 518,293 individual non-overlapping clones with a median insert size of 33 kb, for a total physical coverage of 6.33 of the haploid reference genome (Supplementary Fig. 12 ). The complement of likely inherited heterozygous variants (SNP and indel, n 5 1.97 3 10 6 ) was ascertained by shotgun sequencing and by cross-referencing with calls made by the 1000 Genomes Project, and then re-genotyped using reads from each clone pool. Alleles that were present at distinct heterozygous sites within a given clone were assigned, or 'phased', to the same inherited haplotype, and the unobserved alleles were implicitly phased to the opposite haplotype. When overlapping clones from distinct pools were merged, this resulted in haplotype blocks with an N50 (the contig size above which 50% of the total length of the haplotype assembly is included) of 550 kb containing 90.6% of heterozygous variants that were probably inherited.
Most of the HeLa genome is present at an uneven haplotype ratio (for example, 2:1 in regions in which copy number 5 3). We sought to exploit the resulting allelic imbalance to phase consecutive haplotype blocks ( Supplementary Fig. 13 ). We first calculated the cumulative allelic ratio among shotgun reads for the SNVs residing in each haplotype block, which clustered closely with the underlying haplotype ratio. For example, in non-LOH regions with a copy number of 3 that have ratios of 2:1 or 1:2, allelic ratios calculated for each block had distributions centred on 0.32 or 0.65, close to the expected fractions of one-third and two-thirds ( Supplementary Fig. 14) . Using these ratios, we merged haplotype blocks into scaffolds covering 1.96 Gb or 90.3% of the non-LOH HeLa genome (scaffold N50 of 44.8 megabases (Mb); Supplementary Table 12 ). The haplotype-resolved scaffolds were then merged with the copy-number map to produce a global, haplotyperesolved copy-number profile of the aneuploid HeLa genome ( Fig. 1a , Supplementary Fig. 15 and Supplementary Table 13 ).
Phasing accuracy was independently confirmed by several methods. First, 99.7% of informative read pairs from 3-kb mate-pair sequencing 
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(each read overlapping a phased site) were concordant with the predicted phase. Second, long-insert single-molecule sequencing (Pacific Biosciences RS; mean, 2.97 kb; 90th percentile, 5.1 kb among informative reads) showed that 97.2% of reads were in perfect agreement with the predicted phase, despite the high per-base sequencing error rate of approximately 15% ( Supplementary Fig. 16 ). Third, examination of allelic state across 47.3 Mb of chromosome 18q, which underwent LOH in HeLa S3 but not in CCL-2, showed that out of the 17,761 affected alleles (heterozygous in CCL-2 but at an allele balance of greater than 0.9 among S3 reads), 99.7% corresponded to those phased together on haplotype A in CCL-2 ( Supplementary Fig. 17 ). Finally, windowed analysis of population allele frequencies revealed probable African or European genetic ancestry across long stretches of the haplotype-resolved genome, consistent with recent admixture and a low switch error rate ( Supplementary Figs 18 and 19) .
To measure the frequency of new mutations in the HeLa genome, we examined amplified haplotypes for de facto somatic mutations occurring during tumorigenesis or early in the cell line's subsequent passaging. Within LOH regions, these appear as polymorphisms; 2,883 such sites (mean, 1.31 per haploid Mb; Supplementary Table 14) were confirmed by clone-pool sequencing and allele frequency in shotgun sequencing ( Supplementary Figs 20 and 21) . In non-LOH regions, in which one haplotype is amplified but both remain present, the majority of observed heterozygous sites are inherited, as reflected by their substantial overlap with variants from the 1000 Genomes Project (86.7%, n 5 2,339,608). Excluding these and sites found in the 11 control genomes, 5,282 sites (mean, 1.32 per haploid Mb) remained at which clones differed in genotype between the two or more amplified copies of the same germline haplotype, with little regional variation in the abundance (Supplementary Fig. 22 ). In summary, 8,165 somatic mutations were validated with an estimated sensitivity of 61.1%, placing an upper bound on the pointmutational burden sustained by HeLa CCL-2 after aneuploidy. Despite many additional doublings in culture, this point-mutation frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes 22 . However, without estimates for parameters such as the number of doublings during tumorigenesis, the count of cells explanted, and the number of passages in culture, this estimate of post-aneuploidy mutational burden cannot be rescaled to a rate per base per division.
Four years after the initial establishment of the HeLa cell line, several additional strains were cloned 23 . One of these, HeLa S3, remains in widespread use today and has been profiled extensively as part of the ENCODE Project. To investigate the divergence between CCL-2 and S3, we carried out shotgun sequencing of S3 to 263 coverage. Outside of S3-specific regions of LOH, 94.5% of rare variants in CCL-2 were shared with S3 (n 5 204,841 sites excluding 1000 Genomes Project and segmental duplications, and requiring $83 coverage in each genome; Supplementary Fig. 23 and Supplementary Table 15 ). Somatic mutations were also shared, though to a lesser degree: 72.4% of clone-confirmed somatic mutations from CCL-2 were found in S3 (n 5 8,054 sites with $83 coverage in S3), consistent with a low rate of somatic SNV accumulation since the strains diverged in 1955.
The copy-number profile of HeLa S3 broadly mirrors that of CCL-2 ( Fig. 1b, and Supplementary Figs 7 and 24 ) as well as eight additional HeLa strains that we sequenced lightly (3.5 to 4.33). We observed some strain-specific differences ( Supplementary Figs 25-27 ), consistent with previous reports of karyotypic heterogeneity both among and within strains. Despite some variability, a copy number of three was the dominant state consistently, with a median of 52% of the genome across the eight strains (range 38-60%), similar to its prevalence in CCL-2 (61%). Gains or losses of entire chromosome arms were observed (for example, chr18q, HeLa S3 (Fig. 1b) , chr9p, CCL-13 ( Supplementary Figs 28 and 29) ), but smaller amplifications and deletions were more common. These may correspond to variability in copy rather than in the content of marker chromosomes present, as suggested by high overall breakpoint concordance between strains (81% of copy-number breakpoints within 61 Mb were present in $2 strains). The additional eight cell lines analysed here were identified in the 1970s 24 as products of HeLa contamination into other tissue cultures in the preceding two decades. Their shared set of structural abnormalities reflects their common origin from small founder populations of contaminating cells and reinforces the view that the structural rearrangements resulting in marker chromosomes arose early and are variable in copy number.
Nearly all cervical cancer is caused by human papillomavirus (HPV) infection. Within HeLa, a partial copy of the HPV-18 genome is integrated at a known fragile site on chromosome 8q24. 21 (refs 25, 26) . Haplotype and copy-number maps indicate that the flanking regions are present at copy number four, at a haplotype ratio of 3:1. To characterize the structure and copy number of the insertion, we included the HPV-18 genome alongside the human reference during alignment of clone-pool reads. By analysing patterns of coverage from breakpoint-spanning fosmid clones, read-depth data and breakpoint sequencing, we generated a structural model for the viral integration ( Fig. 2a, b , and Supplementary Figs 30 and 31 ). Two repeat structures (which we designate R1 and R2) consisting of the partial viral genome are interspersed with regions of human chromosome 8q24.21 genomic DNA. The viral genome is present with identical breakpoints on each copy of the amplified haplotype, to the exclusion of the other haplotype, which remains at single copy and lacks integration-associated rearrangements, confirming that integration and rearrangement preceded aneuploidy. The integrated structure contains only two-thirds of the complete HPV-18 genome, including full-length copies of the E6 and E7 oncogenes necessary for telomerase activity (amplified to a copy number of approximately 12), but lacking a functional copy of E2, an inhibitor of E6 and E7 (ref. 13) (Fig. 2c) . In addition, a distinct portion of the HPV-18 genome, amplified to a copy number of approximately 30 in HeLa, includes an epithelium-specific enhancer 
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that controls E6 and E7 transcription 27 , possibly contributing to their high expression ( Supplementary Fig. 32 ). Extensive sequencing-based functional genomic data have been generated on HeLa and other cancer cell lines by the ENCODE Project 7 , but these have the potential to be misinterpreted if their analysis does not account for aneuploidy and phase. As HeLa CCL-2 and S3 are nearly identical in genotype, we used haplotype and copynumber maps of CCL-2 to assign phase to publicly available functional data generated on S3 (ref. 7) , including transcription-factor binding, chromatin modification and chromatin-accessibility data sets. We also calculated haplotype-specific gene-expression scores using RNA sequencing (RNA-seq) data generated in this study and by others 6, 7 ( Supplementary Figs 33-35 ). For each data set, aligned reads were phased by comparison to HeLa CCL-2 haplotype blocks. Corresponding peak scores (chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) and DNase I sequencing (DNase-seq)) or gene-expression values (RNA-Seq) called from the full set of reads were divided proportionally based on the abundance of phase-informative mapping to each haplotype, normalized to each haplotype's estimated copy number. Mapping to the human reference genome imposed a slight bias, favouring the reference allele by an average of 1.08-fold. We constructed two HeLa-specific reference sequences by introducing all SNVs from each haplotype onto one or the other; mapping to this reference mitigated most of the bias (to 1.02fold, or a 75% reduction; Supplementary Figs 36-38 ).
Across the HeLa genome, gene expression is significantly correlated with copy number (P 5 0.075; Fig. 3a, b ), suggesting a minimal role for gene-dosage buffering. Moreover, on average, each haplotype copy makes a comparable contribution to the transcriptome, despite uneven amplification and, in some cases, rearrangement (Fig. 3c, e ). This trend is also observed for histone modifications, DNase hypersensitivity and transcription factor binding ( Supplementary Figs 39 and 40 ). Transcript allele balances at sites heterozygous in CCL-2 on chromosome 18q closely followed the genomic balance (mean 66% representation of the A allele (two-thirds was expected)), but S3 nearly exclusively matched the A allele (94% of reads), reflecting the S3specific LOH event (Fig. 3d ). However, a small number of regions showed strong imbalances between each haplotype's contribution to overall patterns of expression, chromatin modification and transcription-factor binding (2.4% of ENCODE peaks, excluding those in LOH regions; Supplementary Figs 41-44 
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500 kb) were among the regions with the most highly haplotypeimbalanced regulation in the genome ( Supplementary Fig. 45 ). Phased RNA-seq data indicate that MYC is highly expressed, but almost exclusively from the HPV-18-integrated haplotype (mean ratio, 95:1; Fig. 4b and Supplementary Fig. 46 ). Phased ENCODE tracks and long-range chromatin interaction data (ChIA-PET (chromatin interaction analysis with paired-end tag sequencing) 28 ; Fig. 4a and Supplementary Fig. 47 ) across the region indicate that transcription-factor occupancy, active chromatin marks and long-distance physical contacts are also nearly exclusive to the HPV-integrated, transcriptionally active haplotype. Taken together, these data implicate viral integration as a strong activator of MYC expression 29 , acting in cis rather than in trans and possibly mediated by the epithelium-specific viral enhancer amplified to a copy number of approximately 30 within the R1 repeat structure (Fig. 2b) 27 . This strong cis interactionbetween the amplified, integrated genome of a DNA tumour virus and a canonical proto-oncogene-may underlie the robust growth characteristics of the HeLa cell line, and provides indirect support for the hypothesis that inherited risk loci for cancer at chromosome 8q24 operate through activation of MYC 30 .
In summary, we present a haplotype-resolved genome and a haplotype-resolved epigenome of a human cancer. Our study not only provides an overdue genomic analysis of the human cell line that is possibly the most commonly used in biomedical research but also represents a unique view into a cancer genome and epigenome enabled by the acquisition of haplotype information.
METHODS SUMMARY
Cells were maintained at 37 uC in DMEM F-12. Shotgun libraries were prepared by conventional ligation-based methods, sequenced on an Illumina HiSeq 2000 instrument. Point variants were called using shotgun sequence reads. Copynumber maps were created from read depth. Long-insert clone-dilution pools were created and analysed as described previously 5 . Data sets used for each analysis are depicted as a flow chart in Supplementary Fig. 48 . Full methods and associated references can be found in the online version of the paper and in Supplementary Notes 1-23.
